Aptevo Therapeutics Inc.
APVO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $71 |
| Gross Profit | $0 | $0 | $0 | -$71 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,044 | $3,328 | $3,633 | $3,880 |
| G&A Expenses | $3,566 | $2,898 | $2,847 | $2,502 |
| SG&A Expenses | $3,566 | $2,898 | $2,847 | $2,502 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$71 |
| Operating Expenses | $7,610 | $6,226 | $6,480 | $6,311 |
| Operating Income | -$7,610 | -$6,226 | -$6,480 | -$6,382 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $61 | $22 | $72 | $70 |
| Pre-Tax Income | -$7,549 | -$6,204 | -$6,408 | -$6,312 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,549 | -$6,204 | -$6,408 | -$6,312 |
| % Margin | – | – | – | – |
| EPS | -2.23 | -8.4 | -87.87 | -86.56 |
| % Growth | 73.5% | 90.4% | -1.5% | – |
| EPS Diluted | -2.23 | -8.4 | -87.87 | -86.56 |
| Weighted Avg Shares Out | 4,049 | 738 | 73 | 73 |
| Weighted Avg Shares Out Dil | 4,049 | 738 | 73 | 73 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $49 | $49 | $61 | $71 |
| EBITDA | -$7,500 | -$6,177 | -$6,419 | -$6,311 |
| % Margin | – | – | – | – |